Neoadjuvant sintilimab combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC): Preliminary results from a phase II study.

被引：0
|
作者：
Guo, Jincheng [1 ]
Qiao, Chengrui [1 ]
Lu, Jiabin [1 ]
Yang, Shiqing [1 ]
Zhang, Boyi [1 ]
机构：
[1] Henan Univ Technol, Affiliated Hosp 1, Jiaozuo, Henan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16008
引用
收藏
页码：E16008 / E16008
页数：1
相关论文
共 50 条
  • [1] A study of neoadjuvant sintilimab combined with chemotherapy TP for locally advanced esophageal squamous cell carcinoma (ESCC).
    Li, Zhao
    Xu, Peng-Fei
    Mao, Wei-Min
    Kuang, YuKang
    Fan, Hai-Yin
    Zou, Bin
    Zhu, Jian-Feng
    Li, Chao
    Cheng, Xiao-Liang
    Liu, Xing-Fei
    Guo, Changying
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16038 - E16038
  • [2] A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
    Gu, Y.
    Chen, X.
    Wang, D.
    Ding, M.
    Xue, L.
    Zhen, F.
    Xu, J.
    Wang, M.
    Li, Y.
    Sun, N.
    Liu, C.
    Xu, L.
    Wang, Y.
    Luo, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1307 - S1308
  • [3] Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): Preliminary results of a preoperative phase exploratory clinical trial
    Dong, Y.
    Luo, J.
    Liu, S.
    Lin, Y.
    Han, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1109 - S1109
  • [4] Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Lv, Huilai
    Tian, Yang
    Li, Jiachen
    Huang, Chao
    Sun, Bokang
    Gai, Chunyue
    Li, Zhenhua
    Tian, Ziqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
    Dong, Y.
    Luo, J.
    Liu, S.
    Han, H.
    Lin, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S866 - S866
  • [6] Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study
    Jin, Peng
    Gao, Yong Sheng
    Fu, Zheng
    Yang, Wen Feng
    Meng, Xue
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Phase-II study of toripalimab combined with neoadjuvant chemotherapy for the treatment of resectable esophageal squamous cell carcinoma.
    Liu, Delin
    Zhang, Qin
    Zhu, Jinghua
    Qian, Ting
    Yin, Rong
    Fan, Zhaohui
    Jiang, Feng
    Li, Houhuai
    Lu, Jianwei
    Cao, Guochun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study
    Zhao, Jinbo
    Yan, Xiaolong
    Bai, Yuquan
    Duan, Hongtao
    Jiang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
    Zhang, Zhi
    Ye, Jinjun
    Li, Hui
    Gu, Dayong
    Du, Mingyu
    Ai, Dashan
    Chen, Wei
    Fang, Ying
    Xu, Xinyu
    Bai, Chenguang
    Zhao, Kuaile
    Zhou, Guoren
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
    He, J.
    Zhao, L.
    Li, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1553 - S1553
12345